Oxford Biomedica, AstraZeneca enter new deal for Covid-19 vaccine

Oxford Biomedica has entered a new three-year Master Services & Development Agreement to potentially manufacture AstraZeneca UK’s Covid-19 vaccines in the future. The latest deal is an extension of an original Master Supply and Development Agreement signed by the parties in September 2020. Under the initial deal, the production of Covid-19 vaccines at the Oxbox facility of Oxford Biomedica is anticipated to conclude in the last quarter of this year. As per this agreement, AstraZeneca had agreed to make an upfront payment of $18.1m (£15m) to Oxford Biomedica as a capacity reservation fee.